

| Investor Relations

Global Bio Frontier **ATGen**

Bring the best diagnostics and therapeutics
in the biotechnology and healthcare industry

Disclaimer

This document was drafted by ATGen (“Company” hereinafter) to be used for the purpose of offering information to institutional investors and general investors. Exporting, copying, or redistributing this material shall be strictly prohibited.

All information related to the business performance and financial performance of the Company contained in this document have been prepared in accordance with GAAP.

“Forecast information” contained herein are information that have not been individually verified. These information includes forecasts of business status and financial results in relation to future events. They are termed “predicted”, “forecasted”, “planned”, “expected”, “(E)”. Above “forecasts” are prone to changes and uncertainties of future business environment and other miscellaneous factors.

Due to such changes and uncertainties, actual business performance may vary gravely from the “forecast information” contained herein. In addition, future outlook are based on present day – when the presentation was given – market status and business strategy. The outcome may vary according to changes in the market strategy and business strategy, which may be done so without prior notice.

Our company or its affiliates, advisors or its representatives, shall not bear any responsibilities for any losses that may occur from utilizing this material (including, but not limited to negligence).

This document does not constitute an offer or solicitation for sale of shares. Any part of this document shall not serve as basis for relevant agreement and investment decisions. All investment decisions to buy stocks shall be made based solely under the investors’ responsibility.



Global Bio Frontier **ATGen**

Bring the best diagnostics and therapeutics in the biotechnology and healthcare industry

| Contents

- **Technologies and Vision**
- **NK Vue Kit**
- **SuperNK Therapy**
- **Appendix**

Technologies and Vision

Global Bio Frontier **ATGen**

Bring the best diagnostics and therapeutics
in the biotechnology and healthcare industry

"Global Leader in Biotech & Healthcare"

Accumulation of R&D know-how

**Research
Reagents Business**



**4,500+ Protein &
Antibody Reagents**

Development of research
reagents for more than 15 years

Base technology for development
of ATGen platform

Stable growth and creating profit

**Immune
Diagnosis Business**




**NK Vue Kit
In vitro Diagnostic Test**

Commercialization of NK cell
activity measurement technology

Exclusive rights and high growth
potential

High growth potential

**Cancer
Immunotherapy
Business**



SuperNK Cell Therapy

NK cell mass production
technology with 99% purity and
high killing ability

Patented culture method and
composition of NK cell

NK Vue Kit

Global Bio Frontier **ATGen**


Bring the best diagnostics and therapeutics
in the biotechnology and healthcare industry



Simple and Easy to Identify NK Cell Activity

NK cell Activity

- Resistance or immunity to cancer or disease
- Ability to respond to cancer cells or virus-infected cells without prior sensitization
- The NK cell activity is more important than the number of NK cells



Advantage of NK cell Activity Test

- Check your body's immunity using a small amount of blood (1ml or 1cc)
- Derive results within 48 hours
- Commercialization of technology that can analyze many specimens through one test run
- Can be tested at any time without any preparation



Various Applications of NK Cell Activity Test



Parallel Check with other tests

- Health screening complementary such as DNA test, Antioxidant test, Biometric Age test
- Regular health checkup
- Independent Medical Checkup Institute including KMI, Hanaro, Hanshin Medipia and etc
- 18 branches of the Korean Industrial Health Association, 16 branches of Korea Association of Health Promotion
- Major General Hospitals' Health Checkup Centers




Pre-Screening

- Screening before PET-CT and CT examination
- For biopsy pre-examination
- Early detection of recurrence
- Colorectal cancer
Gastroenterology journal in Jun, 2017 (Canada)
JGH journal in Oct, 2017 (Korea)



Complementary Diagnostics

- Tested with tumor marker tests
- Sensitivity and specificity improvement
- Prostate cancer
Can J Urol journal in May, 2017 (Canada)
- Stomach cancer
Oncotarget journal in Sept, 2017 (Korea)



Monitoring on treatment

- Predicting effects on various drugs and treatments
- Monitoring after chemotherapy
- Monitoring Pre-chemotherapy treatment
ESMO (European Society for Medical Oncology) Poster in Sep, 2017 in Spain
(Denmark Vejle Hospital / Dr. Torben)

Domestic and Overseas Clinical Trials

Prognosis of liver cancer patients and recurrence prediction



NK cell activity in ovarian cancer patients



Prognosis of multiple sclerosis



Association with lung cancer imaging diagnosis



Usefulness as a colorectal cancer screening test



Severity analysis with patients with malignant pancreatic cancer



Monitoring of Triple-Negative Breast Cancer Patients



Usefulness as a diagnostic test for high-risk colorectal cancer



Usefulness as a diagnostic tool for lung cancer



Follow-up and customized treatment of brain tumor patients



Comparison image of prostate cancer and benign prostatic hyperplasia



Pre-screening for PET-CT/CT image of colorectal, breast, and lung cancer



Follow-up of prognosis in patients with hematopoietic stem cell transplantation



Prognosis of End-stage Renal Failure Hemodialysis Patients




Usefulness as a diagnostic tool for prostate cancer



Monitoring of antibody therapeutic reactivity in cancer patients



Domestic Clinical Trials In Plan



Domestic Hospitals and Clinics with NK Vue

Seoul / Gyeonggi / Chungcheong province

University Hospital

Gangnam Severance Hospital, Seoul St. Mary's Hospital, Konkuk University Medical Center, Yoida Mokdong Hospital, Kangbuk Samsung Hospital Suwon Medical Center, Inha University Hospital, Gachon Gil Hospital, Catholic University Incheon St. Mary's Hospital, Chungnam National University Hospital

Health check-up Center

Korea Industrial Health Association (5 branches), Korean Association of Health Promotion (2 branches), Hanaro Medical Foundation (2 branches), Korea Medical Institution (3 branches), Hansin Medipia

Honam / Jeju province

University Hospital

Chonnam National University Hwasun Hospital, Cheju Halla General Hospital, Mokpo Korean Hospital, Yeosu Korea Hospital

Health check-up Center

Korea Industrial Health Association (3 branches), Korea Association of Health Promotion (2 branches), Korea Medical Institution (1 branch)

Yeongnam / Gangwon province

University Hospital

Dong-A University Hospital, Pusan National University Hospital, Kosin University Gospel Hospital, Paik Hospital Medical Center, Yangsan Pusan National University Hospital, Ulsan University Hospital Medical Center, Yeungnam University Hospital

Health check-up Center

Korea Industrial Health Association (5 branches), Korea Association of Health Promotion (3 branches), Korea Medical Institution (2 branches)

University Hospital

Gangnam Severance Hospital, Kangbuk Samsung Hospital, Yoida Mokdong Hospital, Seoul St. Mary's Hospital, Donga University Hospital, Pusan National University Hospital, etc.

General Hospital

NK cell activity test Hospital :
Hyosung Hospital, Incheon Hanlim Hospital, Sung Min Hospital, Worldwide Hospital


Health Check-up Center

Korea Medical Institution, Hanaro Medical Foundation, Hanshin Medipia, Korea Industrial Health Association, Korea Association of Health Promotion

Clinical Laboratories Services


Green Cross Laboratories, Samkwang Medical Laboratories, Soul Clinical Laboratories, Seegene Medical Foundation, EONE Laboratories

Number of NK Vue test sites by Year



[Unit : # of sites]

Global Networks for NK Vue



SuperNK Therapy

Global Bio Frontier **ATGen**

Bring the best diagnostics and therapeutics
in the biotechnology and healthcare industry

Advantages of SuperNK Therapy

01

Mass Production Available

NK cells proliferate at 1,000 to 10,000 times the source amount

02

Superior Killing Ability

SuperNK cells display superior killing ability against cancer cells

03

Ability to Destroy Solid Cancers

Confirmed its ability to destroy a variety of solid cancers including lung, colorectal, breast, and liver cancer

04


Increased Persistence and Expansion in Cancer Patients

Improve immunity in cancer patients

SuperNK

A New Immune Cancer Therapy

Developed an **optimal anti-cancer immune therapy** that composed of **99%** pure NK cells to kill cancer cells



Global Plan for SuperNK

Autologous NK Cell therapy is **currently legal** in Japan, Thailand, Italy, Mexico

- Initiated autologous treatment in Tokyo in March 2018 and will begin treating United States Patients as of June 2018 (inject in Mexico).
- Will begin IRB approved clinical trials in Thailand (Ramathibodi Hospital), Mexico (Angeles Hospital), and Italy in early summer 2018 for cancer, rheumatoid arthritis, Alzheimer's disease, and combination therapy.
- To submit US and Korean FDA IND application by late summer/early fall 2018.
- Plans to do most phase II trials in US and Korea.

NK Cells Play a Major Role in Response to Antibody Therapy in Cancer





Figure 4 | Schematic representation summarizing the different NK cell-based therapeutic approaches. These strategies could be combined for optimal antitumour immune responses. Many natural killer (NK) cell receptors are also expressed on T cells, and T cells can also be transduced with chimeric antigen receptors (CARs) based on NK cell receptors; therefore, these immunotherapeutic combinations might involve both NK cells and T cells. KIR, killer cell immunoglobulin-like receptor; MHC, major histocompatibility complex; NCR, natural cytotoxicity receptor; NCRL, NCR ligand; NKG2DL, NKG2D ligand; PD1, programmed cell death protein 1; PDL1, PD1 ligand 1.

Antibody-dependent cell-mediated cytotoxicity (ADCC) requires competent NK cells!

Response to Herceptin in Metastatic Breast Cancer

Table 1 Pivotal Clinical Trials of Trastuzumab for Metastatic Breast Cancer

	Cobleigh et al 1999[16]	Vogel et al 2002[17]	Baselga et al 2005[18]	Slamon et al 2001[15]
Phase	II	II	II	III
Patients enrolled	222 ^a	114 ^b	105 ^c	469 ^a
Line of therapy	2nd/3rd	1st	1st	1st
Intervention	Weekly T	Weekly T	T every 3 wks	Weekly T with chemotherapy vs chemotherapy alone
ORR ^d	15%	26% (35%)	19% (23%)	50% vs 32% ($P < .001$)
OS	13 mos	24.4 mos	Not reached	25.1 vs 20.3 mos ($P = .01$)

ORR = objective response rate; OS = overall survival; T = trastuzumab (Herceptin).


^aEnrolled patients were not selected for human epidermal growth factor receptor 2 (HER2) overexpression.

^bEnrolled patients were not selected for HER2 overexpression, but retrospective analysis assessed the association of HER2 overexpression and clinical activity.


^cEnrolled patients were required to have HER2 overexpression, but discordance between local and central testing was noted.

^dORRs in parentheses are for confirmed HER2 overexpression.

NK Cells Regulate T Cells




[Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proc Natl Acad Sci U S A. 2016 May 24;113(21):E2973-82.]




["Natural Regulators": NK Cells as Modulators of T Cell Immunity. Front Immunol. 2016 Jun 14;7:235.]

Market Classification of Cancer Immunotherapy

Autologous Immune Cell



Allogeneic Immune Cell



Global Market Strategy for SuperNK Therapy

Autologous

Japan



- Founded NKMAX Japan
- Founded ATGen Japan
- Cell Expansion facility in Tokyo
- Commercialization started in Q1 2018

Thailand



- IRB Approved Clinical Trial in 2018

EU



- Plan Commercialization in 2018

Mexico



- Commercialization starts in Q2 2018
- Supply contract with Hospital Angeles
- Supply US produced GMP products

Italy









- IRB Approved Clinical Trial in 2018

Russia



- Plan Commercialization in 2018

Allogeneic

2018	2019	2020~
KOREA  Apply for IND Phase I clinical trial	KOREA  Phase I/IIa clinical trial	KOREA  Phase IIb clinical trial Apply for NDA
MEXICO  Apply for IND Phase I clinical trial	USA  Apply for IND Phase I/IIa clinical trial	USA  Phase I/IIa clinical trial

Appendix

Global Bio Frontier **ATGen**

Bring the best diagnostics and therapeutics
in the biotechnology and healthcare industry



Infinite Growth with Constant Changes and Challenges

Building Foundation (Start-2005)

- 2002** ATGen founded
Venture Company Certification
- 2003** R&D center certification
- 2004** Reagent supply agreement
signed with overseas companies
- 2005** Patent registration completed for
4 patents

Growth (2006-2010)

- 2006** Designated as Promising Export
Company
- 2007** INNO-BIZ Certified
- 2008** Patent registration completed for
5 patents
- 2009** Developed test kit for influenza
enzyme linked immunosorbent assay
Established Direct online sales system
- 2010** About 100 overseas client companies

Global Expansion (2011~)

- 2011** Patent application [Cancer Diagnosis Method that
measures NK Cell Activity]
- 2012** Overseas revenue \$1M
NK Vue® Kit manufacturing facility / Approval from Ministry of
Food and Drug Safety in Korea
- 2013** Selected as promising SME by Gyeonggi-do (province)
ISO 13485 certification
- 2014** Set up ATGen Canada
New Health Technology approved in Korea
GMP certificate, Canada ISO certification
Europe CE certification
- 2015** ATGen Listed in KOSDAQ
- 2016** NKMAX, an ATGen affiliate company (NK Cell Therapy
Company) founded.
NK Vue® public reimbursement in Korea
- 2017** NK Vue® supply agreement signed with USA, Indonesia,
and Kazakhstan
NK Vue® supply agreement signed with major commercial
laboratories in Korea
NK Vue® product approval in Thailand
NK Vue® product approval / public reimbursement in Turkey
Set up ATGen Japan



Company Profile

— ATGen

Company	ATGen Co., Ltd.
CEO	Sang Woo Park
Established	January 14, 2002
Employees	112 (as of December 31, 2017)
Headquarters/ Factory	<ul style="list-style-type: none"> Headquarters : 6F/1F SNUH Health Care Innovation Park, 172 Dolma-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea Factory : KoreaBioPark, Sampyung-Dong, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
Corporation	<ul style="list-style-type: none"> USA : Los Angeles, California Canada : Laval, Quebec Japan : Tokyo
Business	Diagnostic Test Kit, Research Reagents, SP Technology related R&D Business

— NKMAX

Company	NKMAX Co., Ltd.
CEO	Sang Woo Park
Established	January 6, 2016
Employees	27 (as of November 31, 2017)
Headquarters/ Factory	<ul style="list-style-type: none"> Headquarters : 1F SNUH Health Care Innovation Park, 172 Dolma-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea GMP : 1F SNUH Health Care Innovation Park, 172 Dolma-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea USA : Irvine, California
Business	Immune Cancer Therapy

More Competitive Together To Provide Total Healthcare Solution

**Diagnostic, Cell Therapy, and Prevention
Promote a Total Health Care Service**

ATGen

In Vitro Diagnostics

Manufacturing
Technology

NKMAX

Highly Active NK cell

Mass Culture
Technology



Innovative R&D Strategy

Continuous
expansion of
platform-based
pipeline
Strengthening R&D
strategy



Expansion to Global Market

Agreement with the
major corporations
and exclusive
distributors in
various countries



Maximizing Synergy Effect

Maximizing synergy
effect in diagnostic and
therapeutic market
Arranging a foundation
of personalized
disease prevention
system



TOP Brand

A goal to become top
brand with
differentiated
marketing strategy

Global Bio Frontier **ATGen**

Bring the best diagnostics and therapeutics in the biotechnology and healthcare industry



| Thank you

Health is the greatest wealth